COST Action CA21151 “Generation of human induced pluripotent stem cells from haplo-selected cord blood samples (Haplo-iPS)” held its third annual Management Committee and Working Group meetings on 15-16 May 2024 in Amsterdam, the Netherlands.
Haplo-iPS network aims to establish a framework for hiPSC generation of hiPSC homozygous for frequent HLA haplotypes, compatible with a significant percentage of the population to be used for cell therapy clinical trials and to create a data collection system (REGISTRY) for such lines. The network includes all the relevant stakeholders: hiPSC generation/banking centres, CB banks that will supply cord blood units, manufacturing centres (GMP complying), immunology experts, chemistry and manufacturing controls, regulatory bodies, National Agencies, and ethics experts.
Haplo-iPS COST Action leaders and members of the seven working groups were welcomed by the Action Chair Dr. Anna Veiga who presented the activities performed under the project for the last year. The meeting continued with group leaders reporting of achievements and planning of the steps during the next annual period. Fruitful discussions from all aspects of the topic of the project were held during the meeting. The meeting also featured a presentation by David Turner, Lead for Histocompatibility and Immunogenetics Services, Scottish Blood Transfusion Service (SNBTS), based in Edinburgh, and representative of GAiT (Global Alliance for iPSC Therapies), on the EU Coverage for iPSC Banks.
The meeting presentations are available in the Haplo-iPS website repository for registered users.
